This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
World CLL Day is Tomorrow!
We are excited to celebrate this important day in partnership with CLL Advocates Network (CLLAN). This first World CLL Day (WCLLD) is a time to improve understanding of the challenges faced by those living with CLL, and to thank those who have become vaccinated, which helps to protect all those who are immunocompromised.
On September 1st, we invite you to participate in this special day by posting on your own social media channels to help spread awareness and show your support for all those living with CLL. Share with #WCLLD21 and #immunitycommunity.
Be sure to watch CLL Society on Facebook and Twitter tomorrow to learn what World CLL Day means and to see the difference we can make for the CLL community.
Patient Research: iwCLL Abstract Accepted
CLL Society is proud to announce that our abstract, A Survey of European Chronic Lymphocytic Leukemia (CLL) Patients’ and Caregivers’ Awareness, Preferences, and Understanding Related to Finite (Limited) Duration Therapy and Minimal Residual Disease (MRD) has been accepted for presentation at the International Workshop on CLL (iwCLL) taking place September 16 – 20, 2021. We are thankful to those of you who participate in CLL Society surveys, as it allows us to present important information such as this to the global CLL community.
COVID-19 Clinical Trial Research News
Robust, pre-exposure prophylaxis with long-acting antibodies, which are able to prevent symptomatic COVID-19, could help open the world for CLL patients! This is why we are pleased to report that the AZD7442 PROVENT Phase III Prophylaxis Trial met its primary endpoint in preventing symptomatic COVID-19, with in- vitro data suggesting it will be effective against the Delta strain. Dr. Koffman was a participant in this trial, which offers hope for the many CLL patients who are not well protected by vaccinations. Please read Dr. Koffman’s write-up here.
Upcoming CLL Society COVID-19 Event
COVID-19 Virtual Community Meeting: The Delta Variant and Staying Protected is taking place Friday, September 24th at 9:00 AM PT, 10:00 AM MT, 11:00 AM CT, 12:00 PM ET. The global COVID-19 pandemic continues in the US due to the increased prevalence of the Delta variant coupled with suboptimal vaccination rates as we enter the fall. It is critical that CLL patients and their caregivers continue to receive up-to-date and credible information from a spectrum of expert voices. Join us for this COVID-19 Virtual Community Meeting, CLL Society’s continuing series, providing information to empower our CLL patient and caregiver community to make safe and informed decisions. CLL patients and caregivers can engage in a question-and-answer town hall format with a panel comprised of two CLL experts, an infectious disease specialist, and a virologist, to discuss the current COVID-19 challenges affecting CLL patients.
Guest Article by Pharmacist Tom Henry
Seven members of the U.S. House of Representatives from both parties have introduced H.R. 4385 to address the high costs some CLL/SLL patients pay for their targeted oral therapies. Having cancer is costly. Many of the best drugs used to treat CLL are oral medications that can be prohibitively expensive because they are paid for through pharmacy benefits, while IV drugs are much less costly to the patient as they are paid as part of the medical benefits. Oral parity legislation aims to fix this inequity. Please take a few minutes to contact your U.S. Representative today.
In case you missed CLL Society’s August 26th webinar featuring Dr. Ian Flinn, you will be happy to know that it is now available on-demand. This topic may be of special interest to those who have relapsed on, or become refractory to, a BTKi drug such as ibrutinib, or the BCL-2 inhibitor venetoclax. The approved PI3 kinase inhibitors duvelisib or idelalisib, and the still experimental umbralisib, offer a potent and potentially helpful third option. Frontload your knowledge about PI3K inhibitors! Revisiting PI3K Inhibitors for the Treatment of CLL: Are They Living Up to Their Promise?
If you missed Navigating Treatment with BTK Inhibitorsled by Dr. Matthew Davids, it is available to watch on-demand. Hear a CLL patient’s perspective on the latest findings on long-term efficacy of BTK inhibitors, side-effect management, and adopting healthy lifestyles to improve outcomes.
CLL Society Support Group Meetings Coming Up!
CLL Society Support Group meetings have moved to a virtual platform for most locations due to the threat of coronavirus. Support group members will receive an invitation to register for the meeting from the support group facilitator. If you are new to the group, please contact the RSVP email for the Support Group in your region. Once it is safe again, we will resume in-person meetings.
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.